* NeoPharm Inc., of Bannockburn, Ill., met with the FDA to discuss the company's new drug application for Neomark (broxuridine), an in vivo prognostic indicator in breast cancer cell proliferation. NeoPharm plans to submit more information and analysis in an attempt to gain marketing approval.

* Siga Pharmaceuticals Inc., of New York, achieved its first research goal in its agreement with Wyeth-Ayerst Pharmaceuticals, a division of American Home Products Corp., of Madison, N.J., and has received an additional research and development payment. The collaboration to discover and develop anti-infectives for prevention and treatment of human and veterinary gram-positive bacterial infections could mean up to $25 million for Siga. (See BioWorld Today, July 17, 1997, p. 1.)

* Acadia Pharmaceuticals Inc., of San Diego, said $1.4 million was invested in the company with the exercise of warrants held by a group of institutional investors who participated in a financing in February 1997. The investors, based in Copenhagen, include BankInvest, a biotechnology mutual fund; Dansk Kapitalanlaeg, a venture capital firm; and institutional investors LD Pension Fund and Municipal Employee Life Insurance Co.

* Allos Therapeutics Inc., of Denver, said preliminary results of a Phase Ib study of its radioenhancement agent, RSR13, showed encouraging clinical response and survival benefit in cancer patients treated concurrently with radiation therapy. RSR13 is a synthetic allosteric modifier of hemoglobin, and is one in a new class of pharmaceuticals. The small molecule works by reducing hemoglobin-oxygen binding affinity and increasing oxygen delivery from blood to oxygen-deprived tissues.

* CV Therapeutics Inc. (CVT), of Palo Alto, Calif., signed a research agreement with the Cleveland Clinic Foundation for the preclinical testing of certain proprietary CVT cell cycle inhibitors, including CVT-313. The companies will evaluate cell cycle inhibitors when used with drug delivery catheters and as coatings on endoluminal stents to reduce the recurrence of restenosis.

* Protein Design Labs Inc. (PDL), of Mountain View, Calif., said Toagosei Co. Ltd., of Tokyo, made a $2 million equity investment in PDL in the fourth quarter of 1997. Toagosei has received 44,568 shares of PDL stock at $44.875 per share. Toagosei signed an agreement for PDL to humanize one of the Japanese company's antibodies.

* Receptagen Ltd., of Edmonds, Wash., settled on terms and conditions for its merger with Scitech Genetics Ltd. (SGL), of Singapore. These will be submitted with a proposal for a one-for-50 consolidation for shareholder approval on March 13. SGL shareholders will receive 6 million post-consolidation common shares in Receptagen at no cost, along with 500,000 common share purchase warrants exercisable at C$7 until March 6, 2001.

* Medical Science Systems Inc., of Newport Beach, Calif., signed the first in what the company expects to be a series of international agreements to market its first product, PST, the only genetic susceptibility test for periodontal disease. The alliance is with Medicadent SA, of Paris. Under terms of the agreement, Medicadent is responsible for all market development in France, where the product is expected to be available by May.

* Mycogen Corp., of San Diego, said a federal district court jury ruled its two patents covering Bacillus thuringiensis gene synthesis technology were invalid and not infringed by two other companies. The technology is used to make plants insect-resistant. Mycogen, which is considering an appeal of the verdict, filed suit in October 1996, claiming St. Louis-based Monsanto Co. and DeKalb Genetics Corp., of DeKalb, Ill., infringed Mycogen's patents.

* Neurobiological Technologies Inc., of Richmond, Calif., was delisted from the Nasdaq Small Cap market, effective Tues., Feb. 3. The company did not meet financial conditions necessary to remain listed on Nasdaq. Its common stock did meet qualifications to be listed on the OTC Bulletin Board under the symbol NTII.

* ProCyte Corp., of Redmond, Wash., completed a Phase II trial of its wound healing compound, Iamin Gel (prezatide copper acetate), for venous leg ulcers. The drug showed statistically significant healing effects compared to control groups. Eighteen patients were studied, after they were randomly assigned to three 12-week treatment groups.

No Comments